Gibbs Wealth Management Invests $894,000 in Repligen Corporation $RGEN

Gibbs Wealth Management acquired a new position in Repligen Corporation (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 5,360 shares of the biotechnology company’s stock, valued at approximately $894,000.

Other large investors also recently modified their holdings of the company. Iron Triangle Partners LP bought a new stake in shares of Repligen in the third quarter worth about $36,091,000. Delta Investment Management LLC bought a new stake in shares of Repligen in the third quarter worth about $6,779,000. Congress Asset Management Co. grew its stake in shares of Repligen by 43.4% in the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after purchasing an additional 66,142 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Repligen by 123.2% in the third quarter. Schroder Investment Management Group now owns 460,609 shares of the biotechnology company’s stock worth $61,570,000 after purchasing an additional 254,212 shares during the last quarter. Finally, Cinctive Capital Management LP bought a new stake in shares of Repligen in the third quarter worth about $3,398,000. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RGEN has been the topic of several recent analyst reports. Barclays cut their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Wells Fargo & Company cut their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. HC Wainwright raised their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. UBS Group cut their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $176.92.

Repligen Stock Performance

Shares of RGEN opened at $120.10 on Friday. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average price is $126.35 and its 200-day moving average price is $146.14. Repligen Corporation has a 52 week low of $109.66 and a 52 week high of $175.77. The stock has a market cap of $6.77 billion, a P/E ratio of 141.29, a P/E/G ratio of 2.34 and a beta of 1.19.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. During the same period in the previous year, the firm posted $0.44 EPS. The business’s revenue for the quarter was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.